Introduction.
Health-related Quality of Life (HRQoL) is a concept that reflects subjective individual perceptions of the effects of an illness and its treatment on physical, mental and social aspects of life [1] . As a result, HRQoL appears to be directly indicative of reduced level of patients' well-being from their disease. Changes may otherwise indicate genuine and meaningful effects of treatments administered. Therefore, use of HRQoL scales has been proposed as an appropriate method to ascertain actual effects on patients' lives, resulting from disease as well as from therapeutic interventions, and should at least complement other health status measurements in neuromuscular conditions. Although an earlier study, which will be detailed as part of the current review, had demonstrated the Medical Outcome Study 36-item short form health status scale (SF-36) Questionnaire as a potentially valuable instrument in inflammatory neuropathies [2] , the extent to which HRQoL evaluations have been used subsequently in the research setting has appeared variable.
Chronic inflammatory neuropathies are a broad and heterogeneous group of conditions manifesting in focal, multifocal or generalized sensory and/or motor deficits, evolving in a progressive or relapsing and remitting manner. In chronic inflammatory neuropathies, different therapies have demonstrated favourable effects on muscle strength and/or neurological function. How relevant these can be in actually improving the day-to-day living of treated patients may however be difficult to ascertain. Furthermore, baseline pre-treatment quality of life characteristics are uncertain in this group of disorders and how that may compare with normative values is unknown. We conducted a systematic review of the literature relating to use of
instruments measuring HRQoL in chronic inflammatory neuropathy, focusing in particular on chronic inflammatory demyelinating polyneuropathy (CIDP) and multifocal motor neuropathy (MMN) . We aimed to specifically analyze the use of HRQoL measures in the studied populations, in relation to baseline function as well as therapeutic benefit and its clinical correlates.
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5 Materials and Methods.
Our search methodology followed the standard guidelines for systematic literature reviews outlined in the PRISMA statement [3] . We conducted a Medline search of all English language articles published between 1966-October 2014 on HRQoL in all forms of chronic inflammatory neuropathies. We used Medline with the search MeSH terms "inflammatory neuropathy", as well as "chronic neuropathy", "paraproteinaemic demyelinating neuropathy" ("PDN"), "POEMS"
("Polyneuropathy, Organomegaly, Endocrinopathy, M-Protein, Skin") syndrome,
"CANOMAD" ("Chronic Ataxic Neuropathy with Ophthalmoplegia, M-protein and
Disialosyl antibodies") syndrome, each combined with "Quality of Life" and "Health
Status". Reference lists of each retrieved paper were screened for additional relevant publications. All papers discussing specifically ascertainment of HRQoL in any aspect of baseline clinical manifestations, treatment effects or disease monitoring, were analyzed. Articles were included irrespective of disease subtype or course, number of patients studied, main purpose of the analysis considered, type of monitoring otherwise performed/described in addition to HRQoL, or type of therapeutic intervention utilized. Papers considered were read in full-text version and analyzed in detail in relation to HRQoL evaluations, results and conclusions.
Reference lists of retrieved articles were searched for any additional relevant publications in the field. The findings are presented here in a descriptive manner following the chronological development of this rapidly expanding field.
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Results.
We retrieved a total of 23 articles which had descriptions of use of instruments measuring HRQoL in patients diagnosed with chronic inflammatory neuropathy. The reviewed articles, summarized in Table 1 . showed heterogeneity in terms of study focus. Some studies described the results of a cross-sectional analysis of HRQoL in patients with CIDP. In other studies, changes in HRQoL were described as part of a 
which is scored separately. In this study there were no significant changes of HRQoL according to the SF-36 physical functioning scores after 6 weeks in either treatment group. In a separate publication [5] , the authors detailed the results of their assessments using the EuroQol (EQ)-5D instrument to ascertain the broader impact of the two interventions. The EQ-5D is a shorter generic HRQoL measure consisting of 5 domains (mobility, self-care, usual activities, pain/discomfort and anxiety/depression), each of which has three levels of severity (1, no problem; 2, some problem and 3, serious problem). As opposed to the findings of treatment equivalence for the primary outcome measure, the EQ-5D was unchanged for the prednisolone group, whilst there was a relatively large improvement in quality of life In a heterogeneous population consisting of 8 patients with CIDP and 3 with MMN, but also 3 with GBS and 10 with myasthenia gravis, improvements of the Italian version of the SF-36 were reported after IVIg therapy [6, 7] . Analysis of changes in SF-36 subscores indicated highly significant differences of vitality, physical role, and
physical function subscores from normal, which all improved after IVIg therapy. On the other hand, the comparison of mental scores between the baseline evaluation and the follow-up evaluation revealed no differences, leading the authors to conclude that IVIg did not improve psychological distress. The lack of data regarding the exact breakdown of different diseases makes it difficult to reach any further conclusions from these two papers. However it is likely that the expected major post-IVIg improvements in patients severely disabled in the acute stages of GBS and myasthenic crises could have biased the results.
In a study of physical training, a 12-week bicycle exercise programme was implemented in 16 patients with GBS with relatively good recovery and 4 with stable CIDP [8] . All were severely fatigued. Besides the Fatigue Severity Score (FSS), Fatigue Impact Scale (FIS), GBS disability score, Hospital Anxiety and Depression Scale (HAD), Rotterdam Handicap Scale (RHS), the SF-36 was also utilized.
Significant improvements from baseline were obtained for FSS, FIS, HAD and RHS for the whole cohort. The PCS, but not the MCS, of the SF-36 improved significantly (p<0.05). Interestingly, in comparison with healthy controls, only PCS were significantly different to baseline in patients, whereas MCS were comparable, although still improved with the intervention. Unfortunately, precise breakdown of results for the SF-36 was not provided in relation to CIDP patients specifically.
The ICE Trial, a randomized, double-blind, response-conditional crossover study of immune globulin IV, 10% caprylate/chromatography purified (IGIV-C
[Gamunex®]) versus placebo was published in 2008 [9] . This was a multicentre international study involving 117 patients recruited across 33 centres. During the first with MMN on regular IVIg treatment were recruited and randomized to receive either IVIg or SCIg and then crossed over to the other treatment [14] . The primary outcome
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13 was the combined dynamometric strength score expressed relative to normal strength in 5-6 affected muscle groups at three joints and at hand grip. Functional scales were utilized as secondary outcomes. In addition, HRQoL was assessed using a validated Danish version of the SF-36 questionnaire. The items were summarized for PCS and MCS. The treatment methods were found to be equally effective with regard to the primary outcome, and, functionally, there were no significant performance differences for the nine-hole peg test or the 10-metre walk between SCIg and IVIg treatment arms. No differences were otherwise ascertained between the two treatments with regard to SF-36 PCS and MCS scores. In another, prospective, single-centre, openlabel interventional study from the Netherlands, 10 patients with MMN were switched from IVIg to SCIg at 50% or 100% of the previous intravenous dose [15] . Results
showed that the primary outcome measure, the MRC sum score, was unchanged at equivalent doses of treatment, and that HRQoL assessment carried out using the SF- SCIg versus 16% SCIg which had allowed reduction in infusion rate [18] . In a single study specifically focusing on quality of life from the U.K., the SF-36 and LQI were used in 16 patients with MMN treated with either SCIg or IVIg [19] . Overall the mean LQI score for the SCIg group was higher than the IVIg group but this did not reach a significant difference (p=0.06). All individual mean item scores were higher in the In the most recent RCT for CIDP from the Italian group, IVIg treatment was compared to intravenous pulsed corticosteroids, using the difference in the proportion of patients discontinuing treatment with IVIg or intravenous methylprednisolone during the 6 months of therapy because of side-effects, intolerance, or inefficacy (defined as the absence of improvement after 2 months or worsening after 15 days) as primary outcome [20] . The results showed that more patients stopped methylprednisolone (11/21) than IVIg (3/24). This result was highly significant (p=0·0085). When adjusted for sex, age, disease duration, comorbidity, modified
Rankin scale and ONLS scores at enrolment, as well as previous treatment with IVIg and steroids, the difference between the two groups remained significant (p=0·007).
Reasons for discontinuation were lack of efficacy (8 in with IVIg (p=0.011), with no significant difference comparing the two treatment arms (p=0.3634), this result contrasting with the previous comparative analysis performed [1] .
A recent cross-sectional analysis from the south-east of England, U.K., studied specifically HRQoL using the EQ-5D instrument, which was completed by 43/50 of patients with CIDP, 26/37 of patients with PDN and 9/19 of patients with MMN to whom it was sent [21] . In all three diseases, limitations in ability to self-care or carry out daily activities and pain were reported in at least 75% of cases. Anxiety and/or depression affected nearly 50% of patients. Difficulty with mobility was experienced in 83% of patients with CIDP, 81% of patients with PDN and 38% of patients with
MMN. Combining data from the three diseases, the utility scores were not significantly related to gender, age, disease duration or, interestingly, IVIg treatment.
The mean utility scores of each of the three diseases were lower than the U.K.
average, but higher than the scores obtained from a cohort of 737 patients with multiple sclerosis and from a cohort of 97 patients with Parkinson's disease from the same country. In keeping with correlations described in other studies with neurological function, HRQoL was significantly higher in patients who were independently mobile or had no upper limb disability.
A Canadian study specifically analysed the relationship between social support and quality of life, as assessed by a disease-specific HR-QoL scale, the Peripheral Neuropathy Quality of Life Instrument-97, in a population of 154 patients with neuropathy, amongst whom 31.9% had diabetic polyneuropathy, 16% CIDP and 9%
PDN, most having [22] . Another recent cross-sectional study from Brazil specifically focused on the minimental status examination (MMSE) and SF-36 scores in a cohort of CIDP patients [23] . The results were unfortunately not adequately detailed for meaningful conclusions. Although scores for various domains were provided, normative values for the relevant Brazilian population were not available for analysis. Comparisons were made with data from Denmark [13] , although, as acknowledged by the authors, these comparisons were likely to be biased cultural differences.
HRQoL measures have only been used rarely in studies of chronic inflammatory neuropathies other than CIDP. In a RCT of cyclophosphamide with prednisolone for polyneuropathy with IgM monoclonal gammopathy involving 35 patients stratified on the basis of their anti-MAG status, the SF-36 was used as a secondary outcome measure [24] , with the Revised Rivermead Mobility Index used as primary outcome.
Interestingly, although no effect could be demonstrated on the primary outcome, the MRC sum score, the sensory sum score and the SF-36 scores significantly improved in the first study phase of 6 months. The SF-36 itself improved by 31 points in treatment group vs. 5 points in placebo group (p=0.03). Similarly, in the latest placebo-controlled RCT of rituximab for anti-myelin-associated-glycoprotein (anti-MAG) neuropathy [25] , no effect could be demonstrated for the primary outcome One important finding of this review relates to the comparative therapeutic studies.
Although it appeared possible that IVIg may offers a better option than steroids for patients with CIDP on the basis of short-term HRQoL data [1] , this was not confirmed with the 6-month data from the latest comparative study [20] . In the economic context of the high costs of IVIg, this latter result, not consistent with the main study findings on the primary outcome, may raise important questions on the appropriateness of choice of first-line therapy for CIDP. Interestingly, in keeping with these findings, the recent cross-sectional U.K. study equally raises the issue of utility of long-term immunoglobulin therapy which, surprisingly, was not found to influence HRQoL [21] . Likewise, SCIg could be of actual greater benefit than IVIg for CIDP and MMN, from a broader HRQoL perspective, from specific standpoints such as the psychological component, the importance of which cannot be discounted when treating disabling diseases. Correlations of HRQoL measures were otherwise consistently found at baseline with strength scores, isokinetic strength and functional scores in CIDP. Longitudinally, changes in HRQoL also correlated with changes in these scales, interestingly including changes in the psychological domain in the
largest study performed to date [11] . This would appear to confirm the applicability and suitability of HRQoL measures and the SF-36 in particular in this setting.
In therapeutic studies for CIDP, the HRQoL findings suggest that these measures, while correlating closely to traditional scales, may in addition provide useful information, not captured by these. The improvement of the MCS on active therapy in the ICE study demonstrates this [11] . The SCIg versus IVIg trials also revealed improved HRQoL for the former, while other scales showed equivalence. Similarly, the latest placebo-controlled trial of rituximab for anti-MAG neuropathy shows a similar positive impact of the active drug on several components of the HRQoL measures [25] . The results may have been also significant globally on the SF-36, with a greater sample size, contrasting again with the results for the primary outcome for this study. ranging from multiple sclerosis (e.g. MSQOL-54 [27] ) to epilepsy (e.g. QOLIE-10
[28]) and movement disorders (e.g. PDQ-39 [29] , PSP-QOL [30] , GTS-QOL [31] ).
Specifically for neuropathy, a HRQoL instrument was developed using the SF-36 as framework [32] . However this 97-item tool has not been used in subsequent studies in chronic inflammatory neuropathies, with the exception of the wider Canadian study described in this review [22] . Its reappraisal for this subset of neuropathic disorders may prove to be helpful in dissecting the selective impact on different HR-QoL domains. Although these disease-specific psychometric tools do not allow comparisons between quality of life in the target condition and other disorders or healthy state, they often capture aspects of HRQoL which are important to particular patient populations and can be overlooked or underestimated when using generic instruments. The development of a disease-specific HRQoL instrument for patients with chronic inflammatory neuropathies, alongside the recently developed R-ODS scales, might likewise allow a more comprehensive assessment of the impact of the condition and its treatment on patients' wellbeing. In general, further prospective studies are needed to ascertain the exact place and potential future role of HRQoL measures in chronic inflammatory neuropathies. Although limited, current available data are of great interest as we believe this review highlights, and raise many questions, including that of the right choices for the primary outcome measures for future therapeutic studies in the field. 
